SmallCaps Podcast

NoviqTech (ASX: NVQ) chief executive officer Freddy El Turk joins Small Caps to discuss the company’s recent moves which are aimed at expanding its blockchain powered ledger and carbon footprint monitoring expertise to the world.

Earlier this week NoviqTech announced is in advanced discussions to list its shares on the OTC market in the United States.

He told the ASX that trading of NoviqTech’s shares on the OTC is aimed at enhancing the visibility and accessibility of the company to North American investors.

That news followed the company revealing it had received strong industry support

for a strategic placement to raise more than $1 million.

The funds were raised to help the company to accelerate the development of its blockchain-powered solutions.

The placement was supported by several industry professionals, most notably by globally renowned investor, Tony G.

Tony G brings to NoviqTech deep expertise in disruptive technologies and an influential network spanning both private and public sectors.

His investment is considered a resounding endorsement of NoviqTech’s strategy to redefine transparency and accountability in sustainability and a commitment to the company’s innovative approach and confidence in blockchain’s transformative potential.

Articles:
https://smallcaps.com.au/noviqtech-enhance-us-investor-visibility-otc-market-listing/
https://smallcaps.com.au/noviqtech-funding-blockchain-innovation-sustainability-initiatives/
https://smallcaps.com.au/cop29-president-warns-road-ruin-leaders-urged-act-climate-crisis/
https://smallcaps.com.au/noviqtech-carbon-central-monitoring-platform-semiconductor-industry/

For more information on NoviqTech:
https://smallcaps.com.au/stocks/asx-nvq/

See omnystudio.com/listener for privacy information.

Boss Energy (ASX: BOE) managing director and chief executive officer Duncan Craib joins Small Caps to discuss the company’s dramatic growth surge with project success in Australia and the US.

Closer to home, Boss’ Honeymoon uranium project in South Australia continues to ramp up its production numbers towards nameplate capacity.

In 2011 Honeymoon became Australia's second operating in-situ recovery uranium mine and earlier this year and it became the nation’s newest uranium producer when Boss leveraged the significant high-quality infrastructure to re-start the valuable asset.

The project’s key metrics continue to be in line with Boss’ targets and the mine is on track to meet the company’s FY25 production guidance.

In the US, Boss is also seeing strong progress at its 30%-owned Alta Mesa project in South Texas.

The recent start-up of production at Alta Mesa is driving ongoing growth and increasing cashflow.

With both projects ramping up production at a time when uranium prices remain strong, Boss is ideally placed to capitalise on the positive outlook for the nuclear sector.

Articles:
https://smallcaps.com.au/boss-energy-strong-progress-honeymoon-alta-mesa-uranium-projects/
https://smallcaps.com.au/boss-energy-further-high-grade-drilling-success-alta-mesa-uranium/
https://smallcaps.com.au/boss-encore-energy-officially-re-open-alta-mesa-uranium-project/

For more information on Boss Energy:
https://smallcaps.com.au/stocks/asx-boe/

See omnystudio.com/listener for privacy information.

Elevate Uranium (ASX: EL8) managing director and chief executive officer Murray Hill joins Small Caps to discuss the upcoming activities at the company's flagship Koppies uranium project in Namibia.

The company is well funded for the next phase of development at Koppies and its U-pgrade™ uranium ore beneficiation process after receiving binding commitments to raise $25 million.

Elevate plans to use the funds to complete a bench-scale metallurgical testwork program on Koppies ore followed by the design, construction and operation of an U-pgrade™ demonstration plant at the project.

The results of which will be used to complete a Koppies scoping study.
The funds will also be used for approximately 100,000 metres of resource and exploration drilling across its Namibian and Australian tenement portfolio.

Koppies' potential was highlighted in a recently announced upgrade of the deposit mineral resource estimate from inferred to indicated status, resulting in 78% of the 66.1 Mlb resource being reported in the indicated category.

Elevate's total Namibian mineral resource has been increased to 112.1 million pounds of uranium.

Articles:
https://smallcaps.com.au/elevate-uranium-boosts-koppies-resource-raises-development/
https://smallcaps.com.au/elevate-uranium-capital-raise-accelerate-koppies-development/
https://smallcaps.com.au/elevate-uranium-upgrades-koppies-resource-indicated-status-78-percent/

For more information on Elevate Uranium:
https://smallcaps.com.au/stocks/asx-el8/

See omnystudio.com/listener for privacy information.

Green Critical Minerals (ASX: GCM) managing director Clinton Booth joins Small Caps to discuss the company's move to acquire a very high-density (VHD) graphite technology.

The innovative technology offers a transformational leap in graphite production and is expected to reach commercialisation within the next 12 months.

Utilising a revolutionary process, the technology produces VHD graphite in just 24 to 36 hours at significantly lower temperatures than conventional methods, providing substantial cost and environmental advantages over competitors.

The addition of the new technology is seen as a “game-changer” for Green Critical Minerals, providing it with the opportunity to make significant strides in the global graphite market.

The company has already identified a path to bring the technology to market as soon as possible.

Green Critical is utilising a deferred structure which ties payments to revenue milestones of $5 million, $20m and $50m in gross revenue to acquire the breakthrough technology.

Article:
https://smallcaps.com.au/green-critical-minerals-acquire-revolutionary-vhd-graphite-technology/

For more information on Green Critical Minerals:
https://smallcaps.com.au/stocks/asx-gcm/

See omnystudio.com/listener for privacy information.

Stormeur (ASX: STR) chief executive officer and chairman Vivek Eranki joins Small Caps to discuss the company's $7 million IPO to fund new Cosmetique clinics on Australia's east coast as part of its growth strategy.

The company recently announced the IPO offering 35 million shares at $0.20 each, aiming to raise funds for clinic expansion, marketing, and potential acquisitions.

Stormeur, which operates 17 clinics across five states, plans to increase its network to 100 clinics by 2025, offering high-end non-surgical cosmetic treatments.

The group has also achieved national safety accreditation, positioning itself as a leader in Australia’s growing non-invasive cosmetic procedure market.

The company plans to list on the ASX under the ticker code 'STR'.

Article:
https://smallcaps.com.au/stormeur-ipo-asx-str-non-surgical-cosmetics-empire/

See omnystudio.com/listener for privacy information.

Australian Rare Earths (ASX: AR3) managing director and chief executive officer Travis Beinke joins Small Caps to discuss the company's continued success at the promising Koppamurra project in South Australia.

The company recently released a 27% increase to the high-grade project's mineral resource estimate of to 236 million tonnes (Mt) at 748 parts per million total rare earth oxides, up from to 186 million tonnes at 712 parts per million total rare earth oxides.

Notably the new mineral resource includes 68 million tonnes grading over 1000 parts per million total rare earth oxides, up 70% on the previous estimate.

Recent exploration has also confirmed higher-grade subsets containing defined thicker areas of continuous higher-grade mineralisation within the resource.

The improved grade and higher-grade tonnage, reinforces AR3’s belief in the project's potential to become a strategically important, long-life supplier of critical rare earths.

In addition, the company has received approval for an exploration program at the southern extension of the Overland uranium project. 

The program will include additional high priority targets in its plans for its first drill campaign set to commence in the coming days.

For more information on Australian Rare Earths:
https://smallcaps.com.au/stocks/asx-ar3/

See omnystudio.com/listener for privacy information.

Lithium Universe (ASX: LU7) chief executive officer Alex Hanly joins Small Caps to discuss the robust results obtained from the company's pre-feasibility study into its Bécancour refinery in Quebec, Canada.

The PFS confirmed the viability - even in a low pricing environment - of this key infrastructure element in Lithium Universe's critical metals development strategy.

The study further confirmed the value of Lithium Universe's counter-cyclical design where it will be able to develop projects at times of low prices that will be well placed when there is a recovery.

The company has also confirmed it is making good progress with offtake discussions with parties interested in its Lithium Conversion Gap strategy.

The company is now focussed on completing a full definitive feasibility study as it closes in on a Final Investment Decision for Bécancour.

Article:
https://smallcaps.com.au/lithium-universe-robust-becancour-refinery-pfs-results/

For more information on Lithium Universe:
https://smallcaps.com.au/stocks/asx-lu7/

See omnystudio.com/listener for privacy information.

Black Rock Mining (ASX: BKT) managing director and chief executive officer John de Vries joins Small Caps to discuss the company's recent signing of a major financing agreement to fund development of the Mahenge Graphite Project in Tanzania.

A consortium of African banks have come together to provide approximately $260 million in loan and bank guarantee facilities to fund Mahenge.

The financial institutions include The Development Bank of Southern Africa, The Industrial Development Corporation of South Africa and Tanzanian lender CRDB Bank.

The new facilities are in addition to around $73 million of previously agreed support from South Korean trading house POSCO, including a $58 million equity investment in Black Rock.

The funding support of the African banks is a major de-risking milestone for Black Rock towards funding the development of the Mahenge project.

Black Rock’s definitive feasibility study for the project has defined a four-stage construction schedule to deliver up to 340,000 tonnes per annum of 98.5% graphite concentrate for 26 years of 98.5% premium graphite flake concentrate with the ability to produce Ultra Purity flake of 99%.

Article:
https://smallcaps.com.au/black-rock-mining-mahenge-debt-financing-facility-african-banks/

For more information on Black Rock Mining:
https://smallcaps.com.au/stocks/asx-bkt/

See omnystudio.com/listener for privacy information.

Tambourah Metals (ASX: TMB) chairperson Rita Brooks joins Small Caps to discuss the company's successful completion of its drilling at the Tambourah Gold project in Western Australia's far north.

The 11 hole RC and diamond drilling program targeted high-grade gold at the historic Tambourah King, Federal and Kushmattie prospects.

A Western Australian government co-funded diamond hole also tested gold mineralisation at the World’s Fair prospect.

The company is expecting assay results from the program to arrive early next month after noting promising geology during the drilling program.

At the same time Tambourah is progressing planning for an RC drill program at the Cheela Gold project and undertaking data analysis and drill targeting of the Bryah Copper-Gold project in WA’s Murchison region.

Article:
https://smallcaps.com.au/tambourah-metals-maiden-drilling-program-namesake-gold-project-wa/

For more information on Tambourah Metals:
https://smallcaps.com.au/stocks/asx-tmb/

See omnystudio.com/listener for privacy information.

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the company's progress with its Stage 2 pivotal GaRP irritable bowel syndrome trial.

The company has made good strides with recruitment for the trial, with over 30 participants enrolled and approximately 20 potential participants currently in the final screening to determine suitability for enrolment.

The company has added additional sites in Adelaide and the Sunshine Coast, while it is receiving sustained levels of interest at existing sites in Melbourne, Sydney, and Brisbane.

The Stage 2 trial is designed to confirm the highly encouraging and clinically meaningful interim results from Stage 1 of the GaRP-IBS clinical trial. 

GaRP is considered to have the potential to be a disease-modifying treatment that aims to positively impact a substantial proportion of the population suffering from the debilitating symptoms of digestive disorders, including irritable bowel syndrome.

Anatara recently received more than $626,000 from the Australian Taxation Office under the Federal Government’s Research and Development (R&D) tax incentive scheme for FY2024. 

Those funds will support Phase 2 of the clinical trial of GaRP.

Articles:
https://smallcaps.com.au/anatara-lifesciences-on-track-recruitment-stage-2-garp-ibs-trial/
https://smallcaps.com.au/anatara-lifesciences-stage-2-garp-trial-ibs-treatment-gains-momentum/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/

See omnystudio.com/listener for privacy information.